簡易檢索 / 詳目顯示

研究生: 董嘉祥
Tung, Chia-Hsiang
論文名稱: 藥用大麻應用於癲癇病症的分析研究
Analysis of Medicinal Cannabis in the Treatment of Epilepsy
指導教授: 王仕茹
Wang, Shih-Ju
學位類別: 碩士
Master
系所名稱: 高階經理人企業管理碩士在職專班(EMBA)
Executive Master of Business Administration
論文出版年: 2019
畢業學年度: 107
語文別: 中文
論文頁數: 80
中文關鍵詞: 藥用大麻大麻素癲癇治療法律
英文關鍵詞: medicinal cannabis, cannabinoids, epilepsy, treatment, legal
DOI URL: http://doi.org/10.6345/NTNU201900013
論文種類: 學術論文
相關次數: 點閱:276下載:9
分享至:
查詢本校圖書館目錄 查詢臺灣博碩士論文知識加值系統 勘誤回報
  • 本研究係在探討藥用大麻對癲癇發作的控制之重要性,分析相關的藥用大麻醫療文獻、報導、研究和訪談。在病例的報告和臨床中顯示,天然的大麻素可以作用於降低人體神經元不正常放電的頻率。併用CBD與AEDs可以在癲癇發作方面發揮控制的作用。本研究以揭開大麻與癲癇之間的關係,促使在醫療上可以開放暨研究藥用大麻對癲癇患者的治療。

    This study explores the importance of medicinal cannabis in the treatment of seizures and analyzes relevant medical marijuana publications, reports, research and interviews. According to several clinical studies, the use of CBD along with AEDs can effectively reduce the frequency of onsets of seizures. This study unveiled the relationship between cannabis and epilepsy, in hope to promote the use of medicinal cannabis in the treatment of patients with epilepsy.

    誌謝 i 摘要 ii Abstract iii 目錄 iv 表目錄 vi 圖目錄 vii 第一章、緒論 1 第一節、研究背景與動機 1 第二節、研究目的 5 第三節、研究流程 7 第四節、名詞定義 8 第二章、文獻探討 10 第一節、人類使用大麻的歷史 10 第二節、大麻的主要成份與人體的反應 13 第三節、癲癇疾病的介紹 21 第四節、藥用大麻對癲癇疾病的效用 25 第五節、抗癲癇藥物的市場概況 32 第六節、台灣對大麻所制定的法律 36 第三章、研究方法 39 第一節、研究架構 39 第二節、研究對象 40 第三節、資料的蒐集和分析 41 第四章、藥用大麻在未來醫療上的研究與探討 45 第一節、證據確鑿的癲癇用藥及Epidiolex的治療費用評估 45 第二節、台灣法律對大麻及其相關製品的探討 47 第三節、未來的研究 55 第五章、結論與建議 56 第一節、研究發現 56 第二節、研究貢獻 59 第三節、研究限制與對未來研究之建議 62 參考文獻 64 附錄 71

    中文文獻
    中央社,2018。泰國批准大麻藥用和研究 東南亞首個合法化國家。https://www.cna.com.tw/news/firstnews/201812250372.aspx
    中央社,2019。浩宇獲准頑性癲癇臨床試驗 預計第2季啟動 最新更新:2019/02/18 20:15 https://www.cna.com.tw/news/afe/201902180287.aspx
    中央社,2019。菲律賓眾議院通過法案 准許大麻醫療使用。https://www.cna.com.tw/news/ahel/201901290317.aspx
    公共政策網路參與平台,2017。將CBD(大麻二酚)列入巴金森氏症和癲癇病患醫療適應症之處方 https://join.gov.tw/idea/detail/44fcf089-c00a-41b4-9791-b816e67f88ee
    台灣藥物臨床試驗資訊網,2010。 A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) in relieving pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. http://www1.cde.org.tw/ct_taiwan/search_case2.php
    台灣癲癇醫學會,2003。92/09/04關於癲癇。http://www.epilepsy.org.tw/ContentAspx/ViewCotent.aspx?pk=003092200003&isClass=6
    江志明、謝惟竣,2018。科學月刊。從古今歷史中認識大麻,第585期:678-681。
    全國法規資料庫,2017。毒品危害防制條例, 修正日期:民國 106 年 06 月 14 日 https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=C0000008
    社團法人台灣癲癇之友協會,2019。癲癇 -- 也是一種病症而已 http://www.epilepsyorg.org.tw/introduction/info.asp?/1.html
    財團法人罕見疾病基金會,2018。《台灣卓飛協會成立大會》記者會。http://www.tfrd.org.tw/tfrd/library_e/content/id/154
    陳亮妤,2018。科學月刊。吸食大麻後的如醉似幻-這是什麼癮頭?,第585期:682-685。
    陳景宗,2018。科學月刊。探究大麻的生理機制與藥理應用,第585期:692-695。
    陳慧慈,2018。大麻概念股開趴 投資人嗨翻天,財訊電子報: 2018-10-31 https://www.wealth.com.tw/home/articles/18367
    雅虎新聞,2018。韓國大麻法修正:2019年開始醫療用大麻合法化!https://tw.news.yahoo.com/%E9%9F%93%E5%9C%8B%E5%A4%A7%E9%BA%BB%E6%B3%95%E4%BF%AE%E6%AD%A3-2019%E5%B9%B4%E9%96%8B%E5%A7%8B%E9%86%AB%E7%99%82%E7%94%A8%E5%A4%A7%E9%BA%BB%E5%90%88%E6%B3%95%E5%8C%96-005800969.html

    董懷仁,2018。美國大麻產業現況分析及未來趨勢,國立臺灣範大學管理學院高階經理人企業管理碩士在職專班碩士論文。
    維基百科,2019。大麻的合法性。 https://zh.wikipedia.org/wiki/%E5%A4%A7%E9%BA%BB%E7%9A%84%E5%90%88%E6%B3%95%E6%80%A7
    衛生福利部國民健康署,2019。108 年 2 月罕見疾病通報個案統計表,108年2月:4。https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=3811&pid=10459

    英文文獻
    Allyn C. Howlett and Mary E. Abood, 2017. CB1 & CB2 Receptor Pharmacology, Adv Pharmacol. 2017; 80: 169–206. https://www.ncbi.nlm.nih.gov/pubmed/28826534
    Andrew Hand, MSc, Alexia Blake, MSc, Paul Kerrigan, BSc, Phineas Samuel, Jeremy Friedberg, 2016. History of medical cannabis. J Pain Manage 2016;9(4):387-394. https://www.researchgate.net/publication/316545890_History_of_medical_cannabis
    BCC Research LLC, 2018. Global Anti-Epileptic Drug Market to Reach $9.5 Billion by 2022, April 04, 2018, Anti-Epileptic Drugs: Global Markets to 2022( PHM197A ). https://www.bccresearch.com/pressroom/phm/global-anti-epileptic-drug-market-to-reach-$95-billion-by-2022
    David Castle and Sanil Rege, 2018. The Psychopharmacology of Cannabis and its Impact on Mental Health – A Primer. Psychscenehub, Posted on September 25, 2018. https://psychscenehub.com/psychinsights/psychopharmacology-cannabis-and-mental-health/
    Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group, 2018. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631. https://www.nejm.org/doi/10.1056/NEJMoa1714631
    Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE Part A Study Group., 2018. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018 Apr 3;90(14): e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14. https://n.neurology.org/content/90/14/e1204
    Ethan B Russo, 2011. Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects, BJP Volume163, Issue7. https://scinapse.io/papers/2148841660
    Ethan B. Russo, 2018. Cannabis Therapeutics and the Future of Neurology, Front Integr Neurosci. 2018; 12: 51, PMCID: PMC6200872, Published online 2018 Oct 18. doi: 10.3389/fnint.2018.00051, PMID: 30405366. https://www.frontiersin.org/articles/10.3389/fnint.2018.00051/full
    EPIDIOLEX (cannabidiol), 2019. EPIDIOLEX® offers dosing flexibility to optimize treatment. https://www.epidiolexhcp.com/dosing-information
    Globenewswire, 2018. GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006. February 21, 2018 16:01 ET | Source: GW Pharmaceuticals plc https://www.globenewswire.com/news-release/2018/02/21/1372900/0/en/GW-Pharmaceuticals-Announces-Preliminary-Results-of-Phase-2a-Study-for-its-Pipeline-Compound-GWP42006.html
    GW Pharmaceuticals plc, 2018. EPIDIOLEX® (cannabidiol) Oral Solution – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S. Press Release, November 1, 2018 http://ir.gwpharm.com/news-releases/news-release-details/epidiolexr-cannabidiol-oral-solution-first-fda-approved-plant
    GW Pharmaceuticals plc, 2018. GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce FDA Approval of EPIDIOLEX® (cannabidiol) oral solution – the First Plant-derived Cannabinoid Prescription Medicine, June 25, 2018. https://www.gwpharm.com/about/news/gw-pharmaceuticals-plc-and-its-us-subsidiary-greenwich-biosciences-announce-fda-approval
    GW Pharmaceuticals plc Press Release, 2018. GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Quarter Ended December 31, 2018 http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-plc-reports-financial-results-and-operational
    Incorpora G, 2009. Dravet syndrome. Ital J Pediatr. 2009 Sep 8;35(1):27. doi: 10.1186/1824-7288-35-27. https://www.ncbi.nlm.nih.gov/pubmed/19737414
    Istok Nahtigal, Alexia Blake, Andrew Hand, Angelique Florentinus-Mefailoski, Haleh Hashemi and Jeremy Friedberg, 2016. The pharmacological properties of cannabis. J Pain Manage 2016;9(4):481-491 https://medreleafaustralia.com.au/wp-content/uploads/2017/11/2.The-pharmacological-properties-of-cannabis.pdf
    Jahngir MU, Ahmad MQ, Jahangir M., 2018. Lennox-Gastaut Syndrome: In a Nutshell. Cureus. 2018 Aug 13;10(8): e3134. doi: 10.7759/cureus.3134. https://www.cureus.com/articles/14127-lennox-gastaut-syndrome-in-a-nutshell
    Kunj Gohil, PharmD, RPh and Devin Enhoffer, PharmD, RPh, 2014. Modest Growth Seen in Epilepsy Market, NCBI, 2014 Nov; 39(11): 786–787. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218674/
    Meir Bialer, Svein I. Johannessen, René H. Levy, Emilio Perucca, Torbjörn Tomson, H. Steve White, 2017. Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). First published: 23 January 2017. https://doi.org/10.1111/epi.13634.
    Moran Hausman-kedem, Shay Menascu, Uri Kramer, 2018. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study. Article in Brain and Development 40(7) · April 2018 DOI: 10.1016/j.braindev.2018.03.013. https://www.brainanddevelopment.com/article/S0387-7604(18)30112-8/fulltext
    Naomi Thomas, CNN, 2018. Are you heavier or shorter than the average American? Updated 1722 GMT (0122 HKT) December 20, 2018 https://edition.cnn.com/2018/12/20/health/us-average-height-weight-report/index.html
    Natalya M. Kogan, Raphael Mechoulam, 2007. Cannabinoids in health and disease, Dialogues Clin Neurosci. 2007 Dec; 9(4): 413–430. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202504/
    Orrin Devinsky, M.D., J. Helen Cross, Ph.D., F.R.C.P.C.H., Linda Laux, M.D., Eric Marsh, M.D., Ian Miller, M.D., Rima Nabbout, M.D., Ingrid E. Scheffer, M.B., B.S., Ph.D., Elizabeth A. Thiele, M.D., Ph.D., Stephen Wright, M.D., for the Cannabidiol in Dravet Syndrome Study Group, 2017. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. The new England journal of medicine, May 25, 2017 vol. 376 no. 21. https://www.nejm.org/doi/full/10.1056/nejmoa1611618
    Peter Loftus, 2018. New Marijuana-Based Epilepsy Treatment to Cost $32,500 a Year - GW Pharmaceuticals CEO says the price was set to be in line with other brand-name epilepsy drugs. THE WALL STREET JOURNAL. Aug. 8, 2018 4:55 p.m. ET https://www.wsj.com/articles/new-marijuana-based-epilepsy-treatment-to-cost-32-500-a-year-1533761758
    ProCon.org, 2013. 10 Pharmaceutical Drugs Based on Cannabis. Last updated on: 11/27/2013 10:44:40 AM PST https://medicalmarijuana.procon.org/view.resource.php?resourceID=000883
    Profofpot, 2016. Trends in Clinical Trials of Medical Cannabis. Clinical Trial ReportsOctober 10, 2016Prof of Pot http://profofpot.com/clinical-trials-medical-cannabis-trends/
    R G Pertwee, 2008. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin, Br J Pharmacol. 2008 Jan; 153(2): 199–215. https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0707442
    Samir Chitnavis, 2019. GW PHARMACEUTICALS: CAMBRIDGE’S MARIJUANA POWERHOUSE. science-entrepreneur TECH SPOTLIGHT 4 FEBRUARY 2019 https://www.science-entrepreneur.com/blog-1/gw-pharmaceuticals
    The Pharmaceutical Journal 2018. FDA grants first approval of a cannabis-derived medicine, Vol 301, No 7915, | DOI:10.1211/PJ.2018.20205071. https://www.pharmaceutical-journal.com/news-and-analysis/news/fda-grants-first-approval-of-a-cannabis-derived-medicine/20205071.article?firstPass=false
    Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group, 2018. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Mar 17;391(10125):1085-1096. doi: 10.1016/S0140-6736(18)30136-3. Epub 2018 Jan 26. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30136-3/fulltext
    Vinod K. Yaragudri, Editor, 2013. Modulation of the Endocannabinoids N-Arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on Executive Functions in Humans, PLoS One. 2013; 8(6): e66387. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066387

    下載圖示
    QR CODE